Cutting-Edge Solutions in Health: Drugs, Deals, and Developments
Read more →
newzly.ai/article/173496…
#HealthSolutions #DrugDevelopment #MedicalDeals
2
Search
Three strikes. Aldeyra's shares have plunged after a third consecutive FDA rejection for reproxalap.
At what point does persistence become a liability to shareholders?
#FDA #biotech #drugdevelopment #clinicaltrials
thepharmaletter.com/pharma-news/al…
Aldeyra shares plunge after third FDA rejection for reproxalap
US biotech Aldeyra Therapeutics (Nasdaq: ALDX) has received a third complete response letter from the American medicines regulator for its dry eye candidate reproxalap, sending shares down around 68%.
From thepharmaletter.com 94
Most Phase 3 trials don’t fail in Phase 3—they fail earlier.
Leading teams are shifting key decisions upstream using modeling to reduce risk before late-stage development.
Read more:
ow.ly/HK4650YzHbL
#DrugDevelopment #MIDD #ClinicalTrials
18
Turn clinical data into life-saving insights!
Enroll now in Clinical Data Management Course & boost your career
Learn More @ shorturl.at/Kq9CO
#DrugDevelopment #ClinicalSciences #SkillUpgrade
3
Discover how strategic partnerships are transforming bioprocessing and biopharma R&D. Watch Dr. Manisha Desai of @bmsnews in our debut BioPharm Drug Digest episode: hubs.li/Q048FFqv0
#BiopharmaPartnerships #DrugDevelopment #BioPharmDrugDigest
12
Novartis to acquire Excellergy for up to $2B for its Xolair successor drug, aiming for faster allergic condition control. #biopharma #drugdevelopment #allergy
$NVS $RHHBY
biopharmadive.com/news/novartis-…
Novartis targets Xolair successor in buyout of startup Excellergy
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.
From biopharmadive.com 62
Could this be a COPD breakthrough? @AstraZeneca’s LUNA program shows tozorakimab (IL-33 mAb) cuts exacerbations in Phase III trials. How will IL-33 blockade impact the industry pipeline? Learn more! hubs.li/Q048FmSB0
#COPD #DrugDevelopment #ClinicalTrials #Biopharma
42
Roche has discontinued the development of its experimental muscle disease treatment, emugrobart, following unsuccessful clinical trial results. The decision was announced by its partner, Chugai Pharmaceutical.
#Pharmaceuticals #DrugDevelopment #ClinicalTrials #Biotech #Roche #Chugai #MuscleDiseases
Source: The Wall Street Journal World News
2
Risk Down. Upside Expanding.
Phase 1 complete. Safety established. Phase 2 underway.
This is where biotech shifts from uncertainty to evidence.
As risk comes down, opportunity expands.
Real data. Real momentum.
#biotech #clinicaltrials #drugdevelopment #biotechinvesting
REG CF Disclaimer: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. Cytonics has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here: rb.gy/24a8ut
3
Traditional #drugdevelopment is slow, costly, and inefficient. 💊
#AI is changing that. 🤖
Discover how AI is reshaping #pharma R&D, real-world use cases, and the challenges ahead.
buff.ly/1mpskdX
Can AI Really Cut Drug Development Time from Years to Months? From eleks.com
11
Bioanalytical strategies are evolving to meet the growing complexity of biosimilar development. Explore the insights in our latest spotlight: ow.ly/iKGL50YyEj0
#Biosimilars #Bioanalysis #DrugDevelopment #Biopharma
2
46
#DrugDevelopment breakthrough: “We’ve found a new way to make precise changes to complex drug molecules, particularly ones that have been exceptionally difficult to modify in the past,” ~ David Vahey, PhD researcher at St John’s College, #Cambridge: ow.ly/mIIR50YsKWA
6
2
.@LumosDX to access $1b US market with diagnostic device, raises $20m. #ASX #Drugdevelopment #MedTech $LDX
stockhead.com.au/health/lumos-t…
Lumos to access $1b US market with diagnostic device, raises $20m | Stockhead
Lumos Diagnostics (ASX:LDX) is breathing new life into diagnostics, landing US CLIA waiver for its flagship product FebriDx
From stockhead.com.au 1
1
852
Calling oncologists, and drug scientists!
Publish your latest findings in #OncologyTherapeutics and #DrugDevelopment a peer-reviewed, open access journal dedicated to advancing #cancercare.
globalmeetx.com/journals/jodd
#ImmunoOncology #PrecisionMedicine #PharmaResearch #CancerDrugs
2
Racura Oncology teams with Purdue Uni to advance cancer drug candidate. #ASX #Drugdevelopment $RAC @RacuraOncology
buff.ly/gkFQNLs
Racura teams with Purdue Uni to advance cancer drug candidate | Stockhead
Stronger together: Racura Oncology (ASX:RAC) teams with Purdue University for molecular level studies on cancer drug research.
From stockhead.com.au 295
Xaira's First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain
@Xaira_Thera
#virtualcell #AI #drugdevelopment
hubs.li/Q048tMk50
Xaira's First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.
From genengnews.com 5
11
516
26
Key Trends Shaping the Future of the Pharmaceutical Industry.
Companies must prepare for heightened scrutiny and demonstrate robust evidence of efficacy and safety across diverse patient populations.
Read More : tinyurl.com/56by8yjz
#PharmaceuticalIndustry #DrugDevelopment
2
Design, Synthesis, and Characterization of Prodrugs of Sulfonamide TLR4 Signaling Inhibitor TAK-242 (Resatorvid)
#DrugDevelopment #MedicinalChemistry #DrugDesign #ProdrugStrategy #InflammationResearch #Immunology #Resatorvid #Pharmacokinetics #DrugRelease #ChemicalBiology
1
77